Related Articles |
TIMP-3 increases the chemosensitivity of laryngeal carcinoma to cisplatin via facilitating mitochondria-dependent apoptosis.
Oncol Res. 2018 Mar 09;:
Authors: Shen X, Gao X, Li H, Gu Y, Wang J
Abstract
Laryngeal carcinoma is a kind of head and neck carcinoma with high incidence and mortality. Chemotherapy treatments ofhuman laryngeal carcinoma may fail due to the development of chemo-resistance. Tissue inhibitor of metalloproteinases 3 (TIMP3) has been shown to be implicated in a number of pathological processes typical for cancer. The present study aims to investigate the involvement of TIMP-3 in chemo-resistance of laryngeal carcinoma. We showed that TIMP3 expression was significantly decreased in chemo-resistant laryngeal carcinoma tissues compared with chemo-sensitivity tissues. Patients with low TIMP-3 expression exhibited poorer overall survival than those with high TIMP-3 expression. Moreover, cisplatin-resistant Hep-2 cells (Hep-2/R) were associated with inhibition of mitochondrial membrane potential (MMP) depolarization after cisplatin challenge. In addition, cisplatin resulted in a more pronounced cytochrome c release from mitochondria to cytoplasm in Hep-2 cells than in their resistant variants. Overexpression of TIMP-3 by adenovirus encoding TIMP-3 cDNA remarkably enhanced cisplatin-induced apoptosis, cytochrome c release and caspase activation in Hep-2/R cells, thereby sensitizing cancer cells to cisplatin. On the other hand, downregulation of TIMP-3 markedly inhibited cisplatin-induced apoptosis in Hep-2 cells through attenuating mitochondria-dependent pathway activation. Taken together, these results demonstrate that decreased TIMP-3 expression may contribute cisplatin resistance via inhibition of mitochondria-dependent apoptosis, indicating that forced TIMP-3 expression may be a useful strategy to improve the efficacy of cisplatin to treat laryngeal carcinoma.
PMID: 29523219 [PubMed - as supplied by publisher]
http://ift.tt/2tAqTTb
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου